Oncology Drugs - France

France

In France, the Oncology Drugs market is forecasted to achieve a revenue of US$5.25bn by the year 2024.
This projection anticipates an annual growth rate (CAGR 2024-2028) of 13.33%, leading to a market volume of US$8.66bn by 2028.
When compared to other countries worldwide, United States is expected to generate the highest revenue in this market, with an estimated amount of US$114,600.00m in 2024.
France is experiencing a surge in the development and adoption of innovative oncology drugs, positioning itself as a leading player in the global oncology market.

Key regions: Germany, India, United Kingdom, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in France has been steadily growing over the past few years, driven by a number of factors.

Customer preferences: Customers in France are increasingly demanding more personalized and targeted treatments for their cancer, which has led to a rise in the use of precision medicine. Additionally, there is a growing preference for immunotherapy drugs, which stimulate the body's own immune system to fight cancer cells.

Trends in the market: One of the main trends in the Oncology Drugs market in France is the rise of biosimilars. These are cheaper versions of existing biologic drugs that have been shown to be just as effective. As the French government looks to cut healthcare costs, biosimilars are becoming an increasingly attractive option. Another trend is the increasing use of combination therapies, which involve the use of two or more drugs to treat cancer.

Local special circumstances: France has a highly developed healthcare system, which provides universal coverage to all citizens. As a result, there is a large market for Oncology Drugs, as patients have access to a wide range of treatments. Additionally, the French government has been actively promoting the use of biosimilars, which has helped to drive down costs and increase access to treatment.

Underlying macroeconomic factors: The French economy has been relatively stable in recent years, which has helped to support growth in the Oncology Drugs market. Additionally, the aging population in France has led to an increase in the number of cancer cases, which has further boosted demand for Oncology Drugs. Finally, the French government has been investing heavily in research and development, which has helped to drive innovation in the industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.